Skip to main content

Table 1 EC50 of DT2216, Bcl-2 family protein inhibitors, or chemotherapy drugs against selective T cell lymphoma (TCL) cell lines

From: DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

TCL cell lines Chemotherapy drugs (nM) Bcl-2 family inhibitors (μM) DT2216 (μM)
Doxorubicin Etoposide Vincristine ABT263 A-1155463 ABT199 S63845 (a selective Bcl-xL
(Bcl-2/xL) (Bcl-xL) (Bcl-2) (Mcl-1) degrader)
MyLa (CTCL) 124.60 199.50 8.60 0.04 0.0008 > 5 > 5 0.005
MJ (CTCL) 480 > 10,000 60 0.33 0.30 > 10 > 10 0.10
MAC2A (ALK-ALCL) 120 1260 < 1 0.06 0.009 1.80 > 10 0.28
L82 (ALK+ALCL) 30 110 < 1 0.07 0.03 2.38 1.55 0.02
DL40 (ALK-ALCL) 10 80 < 1 4.42 > 10 > 10 0.003 > 10
SMZ1 (PTCL-NOS) 10 100 1.50 9.71 > 10 > 10 0.05 > 10
FEPD (ALK-ALCL) 60 370 10 7.90 > 10 8.99 0.22 > 10
Human PLT 0.13 > 10
  1. The results were calculated from a representative experiment with 6 replicates per concentration for each compound. Similar results were also got in two or more assays
  2. EC50 the half maximal effective concentration, CTCL cutaneous TCL, ALK-ALCL anaplastic lymphoma kinase negative anaplastic large cell lymphoma, ALK+ALCL anaplastic lymphoma kinase positive anaplastic large cell lymphoma, PTCL-NOS peripheral TCL not otherwise specified, PLT platelets